Search
Pentoxifylline
go.drugbank.com/drugs/DB00806ApprovedInvestigational[A226608] Pentoxifylline has been marketed in Europe since 1972; PTX extended-release tablets sold under the trade name TRENTAL by US Pharm Holdings were first approved by the FDA on Aug 30, 1984, but
Ferric pyrophosphate citrate
go.drugbank.com/drugs/DB13995Approved[L1419] It is also FDA approved since 2015.[FDA label]
Zopapogene imadenovec
go.drugbank.com/drugs/DB24672ApprovedInvestigationalFood and Drug Administration (FDA) for the treatment of adults with RRP, receiving full FDA approval on August 15, 2025.[L54081]
Phenylephrine
go.drugbank.com/drugs/DB00388ApprovedInvestigational[A187376] Phenylephrine was granted FDA approval in 1939.[L9413] … Phenylephrine is an alpha-1 adrenergic receptor agonist used to treat hypotension,[L9416,L9410] dilate the pupil,[L9413] and induce local vasoconstriction.
Mixtures: PIM-TRA-KOL FLU, NEO PIM-TRA-KOL RASA MELONCategories: Adrenergic alpha-1 Receptor AgonistsALTU-135
go.drugbank.com/drugs/DB05330InvestigationalALTU-135 has been granted orphan drug and fast-track designation as well as CMA Pilot 2 program status by the Food and Drug Administration (FDA).
Panitumumab
go.drugbank.com/drugs/DB01269ApprovedInvestigationalPanitumumab was granted FDA approval on 27 September 2006.[L17663] … Panitumumab (ABX-EGF) is a recombinant human IgG2 monoclonal antibody that binds specifically to the human epidermal growth factor receptor (EGFR). This drug is an antineoplastic agent.
Categories: Epidermal Growth Factor Receptor Antagonist, EGFR (Epidermal Growth Factor Receptor) inhibitorsBrodalumab
go.drugbank.com/drugs/DB11776ApprovedInvestigationalBrodalumab was FDA approved in February, 2017 as Siliq for the treatment of moderate-to-severe plaque psoriasis.
Categories: Interleukin-17 Receptor A Antagonist, Interleukin 17 Receptor A AntagonistsDiiodohydroxyquinoline
go.drugbank.com/drugs/DB09115ApprovedIodoquinol is not currently available in any FDA-approved products.
Piflufolastat F 18
go.drugbank.com/drugs/DB14805ApprovedInvestigationalIt was first approved by the FDA in May 2021 under the brand name Pylarify and aims to allow for earlier and more accurate detection of suspected prostate cancer metastases or recurrences.
Doripenem
go.drugbank.com/drugs/DB06211ApprovedWithdrawnDoripenem injection was approved by the FDA in 2007 to treat complicated urinary tract and intra-abdominal infections. … The FDA revised the doripenem label in 2014 to include a warning against use in ventilator-associated pneumonia and to reiterate its safety and efficacy for its approved indications.